Clinical trials
TACE clinical trials
Below are recruiting tace clinical trials, each written for real people, not researchers. We’re tracking 79 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04996914Recruiting
Radiation after chemo-embolization for liver cancer patients
This trial studies giving targeted radiation after a liver procedure called trans-arterial chemoembolization for hepatocellular carcinoma (HCC). It may help control the cancer in people who cannot have surgery or transplant.
Aachen, North Rhine-WestphaliaAges 18–80 - NCT04512846Recruiting
Radiation for large liver cancer, with or without chemo
This trial compares two treatment approaches for large hepatocellular carcinoma (HCC), a type of liver cancer: stereotactic body radiation therapy (SBRT) alone versus SBRT plus TACE, a catheter-based chemo treatment. It may help decide which approach works better for controlling the tumor when surgery isn’t a good option.
BeijingAges 30–80 - NCT06844357RecruitingPhase 2/Phase 3
New embolization vs standard for liver cancer
This trial tests a new embolization treatment (TATE) against standard therapy for people with intermediate-stage liver cancer that hasn't spread. The goal is to see if TATE works better at controlling the tumor.
Nanjing, JiangsuAges 18 years+ - NCT07489976RecruitingPhase 2
Study of durvalumab for advanced liver cancer not treatable by surgery
This trial tests the drug durvalumab in people with advanced liver cancer (HCC) that has spread beyond the liver and cannot be removed by surgery. It aims to see if durvalumab can help shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06995105RecruitingPhase 1/Phase 2
Personalized mRNA Vaccine for Advanced Liver Cancer
This trial tests a personalized mRNA vaccine made from your tumor's unique genetic markers. It is for people with advanced liver cancer who have not yet received any treatment.
Hangzhou, ZhejiangAges 18–75 - NCT07064681Recruiting
AK104 plus TACE for resectable liver cancer
This trial tests whether adding an immunotherapy drug (AK104) to a standard liver cancer treatment (TACE) helps prevent the cancer from coming back after surgery. It is for people with early-stage liver cancer that can be surgically removed and who have a high risk of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT07408804Recruiting
Lenvatinib alone vs. with chemoembolization for liver cancer
This trial compares the combination of two treatments—chemoembolization (TACE) and lenvatinib—against lenvatinib alone for people with liver cancer that cannot be removed by surgery. It aims to see if the combination works better.
DhakaAges 18–75 - NCT03812874RecruitingPhase 1/Phase 2
Drug after chemo-embolization for liver cancer that can’t be removed
This Phase 1/2 study tests PTX-9908 (a study drug) to see if it’s safe and effective when given after TACE, a liver-directed treatment. It may help people with liver cancer that can’t be surgically removed and who have recovered enough from their recent TACE.
New Taipei City, TaiwanAges 20 years+ - NCT05608213RecruitingPhase 3
Lenvatinib plus radiation seeds vs lenvatinib alone for liver cancer
This Phase 3 trial compares lenvatinib plus implanted radiation seeds versus lenvatinib alone in people with liver cancer that no longer responds to TACE. It aims to improve how long patients can control the cancer inside the liver.
Guangzhou, GuangdongAges 18–75 - NCT05984511Recruiting
Combined treatment for liver cancer with portal vein tumor thrombus
This trial tests whether adding immunotherapy (atezolizumab/bevacizumab) and a type of internal radiation (I-125 seeds) to standard chemoembolization (TACE) can help people with liver cancer that has spread into the main liver blood vessel (portal vein). It aims to control the tumor and improve outcomes.
Guangzhou, GuangzhouAges 18–75 - NCT06031285RecruitingPhase 2
Perioperative immunotherapy plus TACE-HAIC for liver cancer with portal vein tumor thrombus
This trial tests a combination of immunotherapy (sintilimab), a targeted anti-angiogenic drug (bevacizumab biosimilar), and liver-directed therapies (TACE-HAIC) before and after surgery for hepatocellular carcinoma that has spread to the portal vein. The goal is to see if this approach improves outcomes for patients with advanced but resectable liver cancer.
Guangzhou, GuangdongAges 18–75 - NCT06311851RecruitingPhase 1/Phase 2
Chemoembolization plus Avastin for liver cancer that spread
This trial tests combining a liver-directed treatment (TACE) with a drug called bevacizumab (Avastin) to see if it helps shrink liver metastases. It's for people whose liver cancer has spread but can't be removed with surgery.
Tehran, Tehran ProvinceAges 18–80 - NCT06561399Recruiting
Triple therapy followed by radiation for liver cancer
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
Fuzhou, FujianAges 18–75 - NCT06593964Recruiting
TACE with a special gel vs standard beads for liver cancer
This trial compares a new gel-like treatment to standard beads for blocking the blood supply to liver tumors during TACE. It may be an option for patients with certain stages of liver cancer who cannot have surgery or other standard treatments.
NanjingAges 18–80 - NCT06602011Recruiting
Triple therapy for advanced liver cancer with bile duct invasion
This study tests a combination of three treatments—TACE (a procedure that blocks blood flow to the tumor), lenvatinib (a targeted therapy pill), and tislelizumab (an immunotherapy)—for people with liver cancer that has spread into the bile ducts and can't be removed by surgery. The goal is to see if this triple therapy helps shrink or control the cancer.
Fuzhou, FujianAges 18–75 - NCT06607120Recruiting
Trial for advanced liver cancer with TACE and immunotherapy
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver or into major blood vessels. It tests combining a procedure called TACE with immunotherapy (PD-1/PD-L1 inhibitors) and targeted drugs to see how well they work together.
Nanjing, JiangsuAges 18 years+ - NCT06669377Recruiting
Combination therapy for liver cancer with main portal vein tumor clot
This trial tests a combination of treatments for liver cancer that has spread to the main portal vein. It uses a special stent, radiation seeds, and targeted therapies to shrink the tumor and improve blood flow. This may help patients who haven't had certain prior treatments.
Nanjing, JiangsuAges 18 years+ - NCT06794073Recruiting
Combination therapy for advanced liver cancer
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06904196RecruitingPhase 2
Lenvatinib with or without internal radiation for TACE-resistant liver cancer
This trial compares two treatments for liver cancer (HCC) that has stopped responding to TACE. One group gets lenvatinib (a targeted therapy pill) plus SIRT (internal radiation beads placed in the liver), and the other gets lenvatinib alone. The goal is to see which combination works better.
Guangzhou, GuangdongAges 18–75 - NCT07145177RecruitingPhase 1
Lu177-PSMA with liver treatment for advanced prostate cancer
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
San Francisco, CaliforniaAges 18 years+ - NCT07198230Recruiting
DEB-TACE therapy for large lymphoma tumors that have returned or not responded
This trial tests a second-line treatment called DEB-TACE (tiny beads filled with chemo placed directly into the tumor's blood supply) for people with large, hard-to-treat lymphoma tumors that have come back or not responded to other therapies. If you have at least one big tumor with good blood supply and have tolerated doxorubicin chemo before, this might be an option.
Fuzhou, FujianAges 18–75 - NCT07235410Recruiting
Body composition study for liver cancer patients having TACE
This trial uses deep learning to analyze body composition from scans in people with hepatocellular carcinoma (HCC) who are undergoing TACE (a treatment that blocks blood flow to the tumor). It aims to predict outcomes better and may help doctors tailor care.
Wuhan, HubeiAges 18 years+ - NCT07293468RecruitingPhase 2/Phase 3
Comparing two treatments for advanced liver cancer
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
Hong KongAges 18–80 - NCT04472767RecruitingPhase 2
Cabozantinib with immunotherapy plus TACE for liver cancer
This trial studies a combination treatment for hepatocellular carcinoma (liver cancer) that cannot be removed with surgery or transplant. It adds cabozantinib and immunotherapy (ipilimumab plus nivolumab) to TACE, a procedure that delivers medicine directly to the liver tumor area.
Orange, CaliforniaAges 18 years+
Hear when a new TACE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tace?
- Yes. Clin2 currently lists 79 recruiting tace studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tace trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tace trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.